share_log

信達生物:自願公告 - 達伯舒(信迪利單抗注射液)新增第七項適應症、達攸同(貝伐珠單抗注射液)新增第八項適應症納入2023年版國家醫保藥品目錄

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE CHINA NATIONAL REIMBURSEMENT DRUG LIST (2023 VERSION) OF TYVYT''S SEVENTH INDICATION AND BYVASDA''S EIGHTH INDICATION

香港交易所 ·  Dec 12, 2023 23:01
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more